Cabaletta Bio Earnings Call Transcripts
Fiscal Year 2026
-
Key clinical milestones include pivotal myositis trial enrollment, upcoming durability data in pemphigus and lupus, and phase I/II results in multiple autoimmune indications. Automated manufacturing with Cellares enables scalable, cost-effective production, while a favorable safety profile and no preconditioning regimen could transform market adoption.
-
The summit highlighted progress in pivotal myositis trials, advances in automated manufacturing, and a strong safety profile enabling outpatient treatment. Regulatory alignment supports single-arm trials, and the commercial model leverages automation for scalability and cost efficiency.
Fiscal Year 2025
-
Rese-cel is advancing through pivotal trials with strong efficacy and safety data, enabling outpatient administration and scalable manufacturing. The commercial strategy leverages a large clinical footprint, automated production, and a compelling value proposition for payers and patients. Early 2026 and 2027 are key milestones for launch and scalability.
-
Recent clinical data in myositis, scleroderma, and lupus support single-arm pivotal trials with strong FDA alignment. Outpatient administration and a younger, privately insured patient base create a favorable commercial model, while manufacturing and supply strategies are set for broad, efficient market entry.
-
Autologous CAR-T therapies are leading in autoimmune disease, with strong efficacy and safety data. The myositis program is advancing toward a 2027 BLA, leveraging outpatient administration and a broad indication strategy for commercial viability.
-
Transformative clinical data in multiple autoimmune diseases has led to strong FDA alignment for pivotal trials, with myositis enrollment starting this year and systemic sclerosis and lupus soon to follow. A no preconditioning approach may enable single-infusion outpatient therapy, while the commercial strategy focuses on rapid expansion and cost efficiency.
-
Multiple pivotal data readouts for Rese-cel in myositis, lupus, scleroderma, and myasthenia gravis are expected in October, with the potential for first-to-market status in myositis and a significant competitive edge if no preconditioning proves effective. Robust enrollment and strong physician interest support an accelerated regulatory path.
-
FDA alignment enables a streamlined registrational path for Resocel in myositis, with two key cohorts and a focus on safety through weight-adjusted dosing. EULAR will showcase new efficacy and safety data, while rapid enrollment and regulatory milestones are expected across multiple autoimmune indications.
-
RESET trial data show high rates of durable remission in autoimmune diseases, with a strong safety profile and rapid patient enrollment. Weight-based autologous CAR-T therapy enables most patients to discontinue all medications, and upcoming FDA discussions will shape pivotal trial design.
-
Rese-cel is advancing rapidly with strong enrollment at 46 US sites and a robust safety and efficacy profile, with most patients discontinuing all medications post-treatment. Key data updates are expected in February, and regulatory discussions with the FDA are planned for the first half of the year.
Fiscal Year 2024
-
Early leadership in cell therapy for autoimmune diseases is driving rapid clinical site expansion and accelerated enrollment. Favorable safety and efficacy data support a differentiated regulatory strategy, with plans for European expansion and innovation in trial design.
-
Recent clinical data show a strong safety profile and complete B cell elimination, enabling drug-free remission in autoimmune patients. Expansion into Europe and plans for FDA engagement in 2025 aim to accelerate registrational trials, with a focus on durable, symptom-free outcomes.
-
CABA-201 demonstrated strong efficacy and a favorable safety profile in refractory autoimmune patients, enabling drug-free clinical responses and steroid tapering. Protocols now include enhanced safety measures, and the program is expanding in Europe with plans for FDA discussions in 2025.
-
A CD19 CAR T therapy is advancing rapidly in autoimmune diseases, with 40 U.S. sites enrolling for 11 indications and a focus on drug-free, durable responses. Upcoming ACR data will cover safety, efficacy, and innovative manufacturing approaches, supporting momentum toward registrational trials.
-
CABA-201 is advancing rapidly in phase I/II trials for four autoimmune diseases, with 28 U.S. sites open and accelerated patient enrollment. Safety protocols were updated after a grade 4 ICANS event, and regulatory feedback has been supportive. Major data updates are expected at ACR in November.
-
The program is advancing rapidly with a large clinical network and multiple INDs for autoimmune diseases. Key safety learnings have led to protocol updates, and a no-preconditioning sub-study in pemphigus could transform cell therapy standards. Enrollment and data generation are accelerating.
-
The company is advancing a broad, multi-cohort clinical program for autoimmune cell therapy, with strong site expansion and early promising safety data. Protocols were updated after a serious adverse event, and new studies, including a no-preconditioning approach in pemphigus, are underway. Significant data updates are expected by year-end.
-
Autoimmune CAR-T development is advancing with CABA-201, leveraging a unique clinical strategy and rapid site expansion. Early data show strong efficacy and safety, with protocol refinements after an ICANS event. Robust data and potential registrational discussions with FDA are expected by year-end.
-
Initial RESET-Myositis and RESET-SLE trial data show CABA-201 is well tolerated, with no serious adverse events, CRS, or ICANS, and demonstrates promising B-cell depletion and early clinical improvements consistent with academic benchmarks. Expansion of clinical sites and cohorts is underway, with further data expected in 2024.